#CVS Health

#CVS Health

CVS Health ( NYSE: CVS) delivered a solid revenue beat in Q4 2025, though adjusted earnings declined year-over-year despite exceeding Wall Street expectations. The 8.2% revenue increase to $105.69 billion marked the company's strongest quarterly top-line growth of the year. However, adjusted EPS of $1.09 declined from $1.19 in Q4 2024, pressured by Medicare Part D headwinds from Inflation Reduction Act seasonality changes.

"We believe that easy access to PrEP medications is critical for Americans who may be exposed to HIV," Gourdine wrote. "Our formularies cover several PrEP options, both injectable and oral. For drugs excluded from our standard formularies, exceptions are available when medically justified."